China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus

China's Guangxi Wuzhou Pharmaceutical bought a 10% stake in Israel's Oramed Pharma for $52 million as well as China rights to two diabetes treatments, Reuters reported. The deal builds on a December 2014 investment of $5 million for a 7% stake in a private placement. Oramed plans a Phase IIb trial of its oral insulin product in the United States this year. Guangxi Wuzhou Pharmaceutical is a subsidiary of Guangxi Wuzhou Zhongheng Group. Report